| [1] |
Yothers G, O’Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, et al. 2011. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. |
| [2] |
Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, et al. 2020. Colorectal cancer statistics, 2020. |
| [3] |
Siegel RL, Miller KD, Fuchs HE, Jemal A. 2022. Cancer statistics, 2022. |
| [4] |
Beijers AJM, Mols F, Tjan-Heijnen VCG, Faber CG, van de Poll-Franse LV, et al. 2015. Peripheral neuropathy in colorectal cancer survivors: The influence of oxaliplatin administration. Results from the population-based PROFILES registry. |
| [5] |
Winkler F, Venkatesh HS, Amit M, Batchelor T, Demir IE, et al. 2023. Cancer neuroscience: State of the field, emerging directions. |
| [6] |
Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, et al. 2014. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. |
| [7] |
Tofthagen C, Overcash J, Kip K. 2012. Falls in persons with chemotherapy-induced peripheral neuropathy. |
| [8] |
Tofthagen C, Donovan KA, Morgan MA, Shibata D, Yeh Y. 2013. Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors. |
| [9] |
Tofthagen CS, Cheville AL, Loprinzi CL. 2020. The physical consequences of chemotherapy-induced peripheral neuropathy. |
| [10] |
Winters-Stone KM, Horak F, Jacobs PG, Trubowitz P, Dieckmann NF, et al. 2017. Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy. |
| [11] |
Cavaletti G, D’Acunti A, Porcu A, Masiello G, del Campo L, et al. 2023. Self-reported assessment of the socio-economic impact of anticancer chemotherapy-related neurotoxicity. |
| [12] |
Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB. 2012. Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. |
| [13] |
Zanville NR, Nudelman KNH, Smith DJ, Von Ah D, McDonald BC, et al. 2016. Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment. |
| [14] |
Smith EML, Pang H, Cirrincione C, Fleishman S, Paskett ED, et al. 2013. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. |
| [15] |
Soveri LM, Lamminmäki A, Hänninen UA, Karhunen M, Bono P, et al. 2019. Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy. |
| [16] |
Usta-Yesilbalkan O, Ozkaraman A, Lafci C. 2019. The evaluation of quality of life associated with peripheral neuropathy in patients with hematologic cancer. International Journal of Caring Sciences 12:395−402 |
| [17] |
Bakitas MA. 2007. Background noise: the experience of chemotherapy-induced peripheral neuropathy. |
| [18] |
Li R, Liu Y, Xue R, Wang Y, Zhao F, et al. 2025. Effectiveness of nonpharmacologic interventions for chemotherapy-induced peripheral neuropathy in patients with breast cancer: a systematic review and network meta-analysis. |
| [19] |
Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, et al. 2020. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: asco guideline update. |
| [20] |
Liu Y, Liu JE, Chen S, Zhao F, Chen L, et al. 2023. Effectiveness of nonpharmacologic interventions for chemotherapy-related cognitive impairment in breast cancer patients: a systematic review and network meta-analysis. |
| [21] |
Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes HS, et al. 2020. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. |
| [22] |
Mayo SJ, Lustberg M, M Dhillon H, Nakamura ZM, Allen DH, et al. 2021. Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group. |
| [23] |
Price DD, Finniss DG, Benedetti F. 2008. A comprehensive review of the placebo effect: recent advances and current thought. |
| [24] |
Smith EML. 2025. Alliance A221805: Duloxetine to prevent oxaliplatin-induced chemotherapy-induced peripheral neuropathy (CIPN)—a randomized, double-blind, placebo-controlled phase II study. |
| [25] |
Tuttle AH, Tohyama S, Ramsay T, Kimmelman J, Schweinhardt P, et al. 2015. Increasing placebo responses over time in US. clinical trials of neuropathic pain. |
| [26] |
Gopalakrishnan M, Zhu H, Farchione TR, Mathis M, Mehta M, et al. 2020. The trend of increasing placebo response and decreasing treatment effect in schizophrenia trials continues: an update from the US food and drug administration. |
| [27] |
Khan A, Fahl Mar K, Schilling J, Brown WA. 2018. Magnitude and pattern of placebo response in clinical trials of antiepileptic medications: Data from the Food and Drug Administration 1996-2016. |
| [28] |
McCrary JM, Goldstein D, Boyle F, Cox K, Grimison P, et al. 2017. Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. |
| [29] |
Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, et al. 2018. Neurofilaments as biomarkers in neurological disorders. |
| [30] |
Andersen NE, Boehmerle W, Huehnchen P, Stage TB. 2024. Neurofilament light chain as a biomarker of chemotherapy-induced peripheral neuropathy. |
| [31] |
Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. 2019. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with alzheimer disease. |
| [32] |
Giacomucci G, Mazzeo S, Bagnoli S, Ingannato A, Leccese D, et al. 2022. Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in Subjective Cognitive Decline and Mild Cognitive Impairment. |
| [33] |
Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, et al. 2019. Neurofilament light chain as a biomarker in neurological disorders. |
| [34] |
Meregalli C, Fumagalli G, Alberti P, Canta A, Chiorazzi A, et al. 2020. Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity. |
| [35] |
Karteri S, Bruna J, Argyriou AA, Mariotto S, Velasco R, et al. 2022. Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel-induced peripheral neurotoxicity in breast cancer patients. |
| [36] |
Huehnchen P, Schinke C, Bangemann N, Dordevic AD, Kern J, et al. 2022. Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy. |
| [37] |
Kim SH, Choi MK, Park NY, Hyun JW, Lee MY, et al. 2020. Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. |
| [38] |
Cavaletti G, Pizzamiglio C, Man A, Engber TM, Comi C, et al. 2023. Studies to assess the utility of serum neurofilament light chain as a biomarker in chemotherapy-induced peripheral neuropathy. |
| [39] |
Cavaletti G, Jann S, Pace A, Plasmati R, Siciliano G, et al. 2006. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. |
| [40] |
Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, et al. 1999. Total neuropathy score: validation and reliability study. |
| [41] |
Alberti P, Bernasconi DP, Cornblath DR, Merkies ISJ, Park SB, et al. 2021. Prospective evaluation of health care provider and patient assessments in chemotherapy-induced peripheral neurotoxicity. |
| [42] |
Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, et al. 2005. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. |
| [43] |
Smith EML, Banerjee T, Yang JJ, Bridges CM, Alberti P, et al. 2019. Psychometric testing of the European organisation for research and treatment of cancer quality of life questionnaire-chemotherapy-induced peripheral neuropathy 20-item scale using pooled chemotherapy-induced peripheral neuropathy outcome measures standardization and alliance for clinical trials in oncology A151408 study data. |
| [44] |
UmanDiagnostics. 2021. NF-light Serum ELISA (RUO), Cat#20-8002. Tvistevagen 48C, Ulmea, Sweden. https://umandiagnostics.com/products/nf-light-serum-elisa |
| [45] |
Adra J, Giglio D, Karlsson P, Zetterberg H, Einbeigi Z. 2024. Blood biomarkers for neuroaxonal injury and astrocytic activation in chemotherapy-induced peripheral neuropathy. |
| [46] |
Velasco R, Marco C, Domingo-Domenech E, Stradella A, Santos C, et al. 2024. Plasma neurofilament light chain levels in chemotherapy-induced peripheral neurotoxicity according to type of anticancer drug. |
| [47] |
Kim SH, Kim KH, Hyun JW, Kim JH, Seo SS, et al. 2022. Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers. |
| [48] |
Velasco R, Argyriou AA, Marco C, Mariotto S, Stradella A, et al. 2023. Serum neurofilament levels correlate with electrodiagnostic evidence of axonal loss in paclitaxel-induced peripheral neurotoxicity. |